Researchers developed a new algorithm that can use a single OCT scan to predict whether a patient with diabetic macular edema is likely to respond to anti-VEGF treatments. They tested it on pretreatment OCT images (top row) and used post-treatment OCT images (bottom row) to track response to treatment. Case 24 and 36 responded to treatment.
Credit: Sina Farsiu, Duke University
New algorithm poised to help doctors individualize treatment for diabetic macular edema
A new approach that uses artificial intelligence to analyze retinal images could one day help doctors select the best treatment for patients with vision loss from diabetic macular edema. This diabetes complication is a major cause of vision loss among working-age adults.
Anti-vascular endothelial growth factor (VEGF) agents are widely used as the first line of therapy for diabetic macular edema, but they don’t work for everyone. There’s a need to identify who would benefit from the therapy because it requires multiple injections that are costly and burdensome for both patients and physicians.
“We developed an algorithm that can be used to automatically analyze optical coherence tomography (OCT) images of the retina to predict whether a patient is likely to respond to anti-VEGF treatments,” said research team leader Sina Farsiu from Duke University. “This research represents a step toward precision medicine, in which such predictions help clinicians better select first-line therapies for patients based on specific disease conditions.”
In The Optical Society (OSA) journal Biomedical Optics Express, Farsiu and colleagues show that the new algorithm can analyze just one pre-treatment volumetric scan to accurately predict whether a patient is likely to respond to anti-VEGF therapy.
“Our approach could potentially be used in eye clinics to prevent unnecessary and costly trial-and-error treatments and thus alleviate a substantial treatment burden for patients,” Farsiu said. “The algorithm could also be adapted to predict therapy response for many other eye diseases, including neovascular age-related macular degeneration.”
Predicting treatment response
The algorithm developed by the researchers is based on a novel convolutional neural network (CNN) architecture, a type of artificial intelligence that can analyze images by assigning importance to various aspects or objects. They used the algorithm to examine images acquired with OCT, a noninvasive technology that produces high-resolution cross-sectional retinal images and is the standard of care for assessing and treating many eye conditions.
“Unlike previously developed approaches, our algorithm requires OCT images from only a single pretreatment timepoint,” said Reza Rasti, first author of the paper and a postdoctoral scholar in Farsiu’s laboratory. “There’s no need for time-series OCT images, patient records or other metadata to predict therapy response.”
The new algorithm preserves and highlights global structures in the OCT image while enhancing local features from diseased regions to efficiently use retinal thickness information. To help with treatment decision making, the researchers incorporated an additional step that looks for CNN-encoded features that are highly correlated with anti-VEGF response.
Testing the algorithm
The researchers tested their new algorithm with OCT images from 127 patients who had been treated for diabetic macular edema with three consecutive injections of anti-VEGF agents. They applied the algorithm to analyze OCT images taken before the anti-VEGF injections, then compared the algorithm’s predictions to OCT images taken after anti-VEGF therapy to confirm whether the therapy improved the condition.
Based on the results, the researchers calculated that the algorithm would have an 87 percent chance of correctly predicting who would respond to treatment. It exhibited an average precision and specificity of 85 percent and a sensitivity of 80 percent.
Next, the researchers plan to confirm and extend the findings from this pilot study by performing a larger observational trial of patients who have not yet undergone treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Diabetic macular edema
- Dyslipidemia May Affect Diabetic Retinopathy Risk in Patients With T2D
An investigation examined associations between dyslipidemia markers and diabetic retinopathy development and progression risk.
- Oculis Reports Q1 2024 Financial Results and Provides Company Updates
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF ...
- Cataract Surgery in Patients With Diabetes and Age-Related Macular Degeneration
Nishal Patel, MBBS, MRCOphth; Gordon Bowler; Tolulope Adeniji; Alex K. Nugent, BSc; Damion Lake, MBBS, MRCOphth; Sobha Seswathi, MBBS, MRCOphth; N. Victor Chong ...
- ARVO 2024: Impact of early intraretinal fluid reduction on one-year outcomes in diabetic macular edema
At this year's ARVO meeting, Dolly Chang, MD, PhD, presented data on the early fluid reduction in patients with diabetic macular edema, and how that correlates with 1-year outcome with a deep learning ...
- EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Shares of EyePoint Pharmaceuticals dropped nearly 30% premarket on Monday after the company said its experimental eye disease treatment failed to meet ...
Go deeper with Google Headlines on:
Diabetic macular edema
[google_news title=”” keyword=”diabetic macular edema” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Diabetes related vision loss
- Type 2 Diabetes
If you have overweight, your doctor will usually recommend weight loss as one aspect of an ... The same is true if you don’t manage your diabetes properly. Vision problems, kidney disease ...
- Blurred vision is a symptom of Diabetes and other conditions
The common eye complaint can affect one and or both of our eyes and is often a sign of an underlying medical condition.
- Spotlight On: Lighthouse Guild
The Lighthouse Guild aims to provide all the services that people with vision loss and blindness need to manage their lives and reach their potential.
- EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Shares of EyePoint Pharmaceuticals dropped nearly 30% premarket on Monday after the company said its experimental eye disease treatment failed to meet ...
- More Than Half of Patients with Vision-Threatening Condition Unaware They Have It
Joslin Diabetes Center investigators’ study finds discrepancies between participants’ eye health status and their self-reported eye health. Read more.
Go deeper with Google Headlines on:
Diabetes related vision loss
[google_news title=”” keyword=”diabetes related vision loss” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]